Stryker announced today that it has completed the acquisition of Cerus Endovascular—a medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms.
Cerus’ CE-marked products, including the Contour neurovascular system and the Neqstent coil-assisted flow diverter, will expand Stryker’s current portfolio of aneurysm treatment solutions, as per a company press release.
Technology for the endovascular treatment of aneurysms has been foundational to Stryker’s neurovascular division, and Cerus’ portfolio will address the growing need for one-and-done intrasaccular aneurysm therapy, the release adds.
“The acquisition of Cerus Endovascular is highly complementary to Stryker’s neurovascular business, and strengthens our haemorrhagic portfolio globally,” said Jim Marucci, president of Stryker’s neurovascular division. “We look forward to working with the Cerus team to deliver on our mission of making healthcare better. Together, we will enable physicians to treat a broader range of aneurysms.”
